DiaMedica therapeutics (DMAC) shareholder TomEnterprise Private AB buys $10M in stock

Published 26/07/2025, 20:22
DiaMedica therapeutics (DMAC) shareholder TomEnterprise Private AB buys $10M in stock

A 10% owner, TomEnterprise Private AB, associated with Thomas Von Koch, reported purchasing 2,857,142 shares of DiaMedica Therapeutics Inc. (NASDAQ:DMAC) common stock on July 23, 2025. The shares were bought at a price of $3.5, with the total transaction amounting to $9,999,997. The stock has since rallied to $5.05, delivering a 20.8% return in the past week. Analysts see further upside, with price targets ranging from $11 to $14. InvestingPro subscribers track insider transactions alongside comprehensive financial analysis.

Following the transaction, TomEnterprise Private AB and Thomas Von Koch indirectly own 8,383,577 shares. The company maintains a strong liquidity position with a current ratio of 8.02 and holds more cash than debt on its balance sheet. Investors should note the upcoming earnings report scheduled for August 6, 2025.

In other recent news, DiaMedica Therapeutics Inc. announced the completion of a $30.1 million private placement, selling approximately 8.6 million common shares at $3.50 per share to accredited investors. The company received net proceeds of approximately $29.9 million, which will be used to fund its clinical development programs for preeclampsia, fetal growth restriction, and acute ischemic stroke. This private placement did not involve a placement agent and is expected to close around July 23, 2025, subject to customary closing conditions. Additionally, DiaMedica reported positive interim results from its Phase 2 study of DM199 for the treatment of preeclampsia, achieving pre-specified safety and efficacy endpoints. This study demonstrated statistically significant reductions in blood pressure and improved uterine blood flow. Following these results, H.C. Wainwright raised its price target on DiaMedica to $12.00 from $10.00, maintaining a Buy rating on the stock. The firm noted the potential of DM199 as a disease-modifying therapy for preeclampsia. These developments reflect DiaMedica’s ongoing progress in advancing its clinical programs and securing financial resources.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.